Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients

Monica Guffanti, Cleta Raffaella De Pascalis, E. Seminari, Giuliana Fusetti, Nicola Gianotti, Dante Bassetti, Andrea Galli, Antonella Castagna, Adriano Lazzarin

Research output: Contribution to journalArticle

Abstract

We studied the pharmacokinetics of amprenavir at doses of 600 mg twice a day or 1200 mg once a day, when co-administered to HIV-positive patients with 400 mg a day of atazanavir without a ritonavir booster. Our preliminary results suggest that amprenavir and atazanavir could be co-administered and that amprenavir could be boosted by atazanavir without the need for ritonavir pharmaco-enhancement.

Original languageEnglish
Pages (from-to)2669-2671
Number of pages3
JournalAIDS (London, England)
Volume17
Issue number18
DOIs
Publication statusPublished - Dec 5 2003

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients'. Together they form a unique fingerprint.

  • Cite this